Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 12/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.42 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26088769 | 0.96 | CHRM4 (0.49) | CHRM1CHRM2CHRM4CHRM3TIPARP | |
| SCHEMBL26089787 | 0.94 | CHRM1 (0.47) | CHRM1CHRM2CHRM4CHRM3TIPARP | |
| SCHEMBL26088682 | 0.93 | CHRM2 (0.47) | CHRM1CHRM2CHRM4CHRM3TIPARP | |
| SCHEMBL26090196 | 0.90 | CHRM2 (0.46) | CHRM1CHRM2CHRM4CHRM3TIPARP | |
| SCHEMBL26086814 | 0.90 | CHRM2 (0.49) | CHRM1CHRM2CHRM4CHRM3TIPARP | |
| SCHEMBL26090282 | 0.90 | CHRM2 (0.49) | CHRM1CHRM2CHRM4CHRM3TIPARP | |
| SCHEMBL26088622 | 0.87 | CHRM2 (0.47) | CHRM1CHRM2CHRM4CHRM3TIPARP | |
| SCHEMBL23744421 | 0.87 | CHRM2 (0.58) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL26089272 | 0.86 | CHRM1 (0.46) | CHRM1CHRM2CHRM4CHRM3TIPARP | |
| SCHEMBL26089534 | 0.86 | CHRM1 (0.46) | CHRM1CHRM2CHRM4CHRM3TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM1 5/4885CHRM2 2/4885CHRM4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.